MRKR is the result of a reverse merger (#msg-144280505); such companies tend to have lower valuations, at least initially, than comparable biotechs who went public via an IPO.
Gritstone Oncology…today announced that the first patient has been dosed with its personalized immunotherapy candidate targeting the patient’s tumor-specific neoantigens, called GRANITE-001.
The Phase 1/2 clinical study, referred to as GO-004, is evaluating GRANITE-001 in combination with immune checkpoint blockade for the treatment of patients with advanced solid tumors, including microsatellite stable colorectal cancer (MSS CRC), gastroesophageal cancer, metastatic non-small cell lung cancer, and bladder cancer.